MedPath

Effects of Bariatric Surgery on Inspiratory Metaboreflex in Obese Subjects

Conditions
Obesity
Metabolic Syndrome
Interventions
Other: Bariatric surgery
Other: Control
Registration Number
NCT03056937
Lead Sponsor
University of Cruz Alta
Brief Summary

The hypothesis of this study is that reductions in body weight could improve inspiratory muscle function attenuating the inspiratory metaboreflex in metabolically healthy obese individuals and obese individuals with metabolic syndrome.

Detailed Description

Introduction: Peripheral metaboreflex activation appears to be exacerbated in obese individuals with metabolic syndrome. Interestingly, bariatric surgery attenuates the peripheral metaboreflex. Obese individuals have impaired inspiratory muscle function, which can be reversed by the reduction in body weight. Therefore, bariatric surgery could attenuate inspiratory metaboreflex in metabolically healthy obese individuals and obese individuals with metabolic syndrome. Objectives: To investigate the effects of bariatric surgery on inspiratory metaboreflex in metabolically healthy obese individuals and in obese patients with metabolic syndrome. Patients and Methods: A sample comprising of 15 obese subjects with metabolic syndrome, 15 obese subjects without metabolic syndrome and 15 healthy nonobese individuals. These subjects will be submitted to pulmonary function, respiratory muscle strength, inspiratory muscle resistance, exercise tolerance, quality of life, autonomic cardiovascular control and the inspiratory metaboreflex evaluation. The evaluations performed in obese patients with and without metabolic syndrome pre-surgery will be repeated 6 months after bariatric surgery.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
45
Inclusion Criteria
  • Body mass index (BMI)> 35 kg / m²
  • Diagnosis of metabolic syndrome
Exclusion Criteria
  • Acute health problems in the last month (viral or bacterial infections, accidents, allergic reactions)
  • Diseases of the nervous system or conditions that affect the understanding or participation in the study
  • Pregnancy
  • Type I diabetes mellitus
  • Arterial hypertension
  • Dyslipidemias
  • Coronary artery disease
  • Left ventricular dysfunction
  • Any condition interfering with locomotion
  • Bronchial asthma
  • Chronic obstructive pulmonary disease
  • Chronic neuropathies
  • Use of drugs such as corticosteroids or bronchodilators
  • Smokers.

Obese without Metabolic Syndrome

Inclusion Criteria:

  • Body mass index (BMI)> 35 kg / m²

Exclusion Criteria:

  • Metabolic Syndrome
  • Acute health problems in the last month (viral or bacterial infections, accidents, allergic reactions)
  • Diseases of the nervous system or conditions that affect the understanding or participation in the study
  • Pregnancy
  • Type I diabetes mellitus
  • Arterial hypertension
  • Dyslipidemias
  • Coronary artery disease
  • Left ventricular dysfunction
  • Any condition interfering with locomotion
  • Bronchial asthma
  • Chronic obstructive pulmonary disease
  • Chronic neuropathies
  • Use of drugs such as corticosteroids or bronchodilators
  • Smokers.

Healthy nonobese subjects

Inclusion Criteria:

  • BMI <25 kg / m²

Exclusion Criteria:

  • Non-smokers
  • Any diagnosed disease.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Obese without metabolic syndromeBariatric surgerybariatric surgery
HealthyControlControl
Obese with metabolic syndromeBariatric surgerybariatric surgery
Primary Outcome Measures
NameTimeMethod
Inspiratory metaboreflex6 monhs

It will be induced through a linear inspiratory resistance of 60% of maximal inspiratory pressure

Secondary Outcome Measures
NameTimeMethod
Inspiratory muscle resistance6 months

It will be evaluated through a protocol with progressive increase in inspiratory resistance.

Autonomic cardiovascular control6 months

It will be determined by spectral analysis

Exercise tolerance6 months

It will be determined by the 6-minute walk test.

Quality of life6 months

It will be determined through the SF36 questionnaire.

Pulmonary function6 months

It will be assessed by spirometry

Respiratory muscle strength6 months

It will be determined by manovacuometry.

Trial Locations

Locations (1)

University of Cruz Alta

🇧🇷

Cruz Alta, Rio Grande do Sul, Brazil

© Copyright 2025. All Rights Reserved by MedPath